NCT05269589Recruiting
Home-based Heat Therapy for Type 2 Diabetes
Impact of a Home-based Heat Therapy Intervention on Markers of Cardiometabolic Function in Adults With Type 2 Diabetes
Source: ClinicalTrials.gov · Last updated 12 May 2026
Brief summary (registry, in English)
Insulin resistance and hyperglycemia predispose individuals with type 2 diabetes mellitus (T2DM) to endothelial dysfunction and a greater risk of cardiovascular diseases (CVD). Increased CVD risk in individuals with T2DM persists despite optimal pharmacological therapy, highlighting the need to identify complementary lifestyle interventions that improve cardiometabolic functions in this population. Evidence from animal models suggests that heat exposure improves metabolic functions. Notably, weekly heat exposure for 16 weeks blunts hyperinsulinemia and hyperglycemia induced by a high fat diet in mice. In parallel, studies in humans have shown that heat exposure improves vascular endothelial function. Based on such findings, it has been suggested that heat therapy may represent an effective lifestyle intervention to improve cardiometabolic functions. However, only 1 study has examined the impact of a heat therapy intervention on individuals with T2DM, demonstrating that 6 weeks of heat exposure reduces fasting plasma glucose and hemoglobin A1C. No study has considered potential vascular benefits of heat therapy in individuals with T2DM. This project will investigate cardiometabolic responses to repeated heat exposure in men and women with T2DM. We will test the hypothesis that 12 weeks of heat therapy improves postprandial fatty acid handling, insulin sensitivity and endothelial function in individuals with T2DM.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 44 (estimated)
- First submitted
- 7 Feb 2022
- Start date
- 18 Feb 2022
- Primary completion date
- Dec 2027
- Lead sponsor
- Montreal Heart Institute
- Diseases
- Type 2 diabetes
- NCT number
- NCT05269589
What you commit to
- Study type: Interventional
- Planned participants: 44
- From 18 Feb 2022 to the primary completion date, Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Insulin therapy
Other illness
- Hypertension not controled by medication
- Diagnosis of cardiac, renal and/or pulmonary disease
Lab values
- Fasting plasma triglycerides \>5.0 mmol/L
- Fasting total cholesterol \>7 mmol/l
Other
- Class 3 obesity
- Diagnosis of severe neuropathy and/or retinopathy
Who the study is looking for
- Age 45-75 years
- Diagnosis of type 2 diabetes mellitus ≥1 year
- Stable medication ≥12 weeks
Age in the registry: 45 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre ÉPIC, Montreal Heart Institute Coordinator of this site? Confirm its status | Montreal | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.